Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma

June 14, 2016
Keith T. Flaherty, MD

Keith T. Flaherty, MD, provides an overview of the phase III COMBI-d study, which examined the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) as a treatment of patients with BRAF-mutant metastatic melanoma.